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Abstract (200 words) 
Background: Alcohol is a well-established risk factor for head and neck cancers (HNC). This study aims to 
explore the effect of alcohol intensity and duration, as joint continuous exposures, on HNC risk. 
Methods: Data from 26 case-control studies in the INHANCE Consortium were used, including  never  and 
current drinkers who drunk ≤10 drinks/day for ≤54 years (24234 controls, 4085 oral cavity, 3359 
oropharyngeal, 983 hypopharyngeal, and 3340 laryngeal cancers). The dose-response relationship between the 
risk and the joint exposure to drinking intensity and duration was investigated through bivariate regression 
spline models, adjusting for potential confounders, including tobacco smoking. 
Results: For all sub-sites, cancer risk steeply increased with increasing drinks/day, with no appreciable 
threshold effect at lower intensities. For each intensity level, the risk of oral cavity, hypopharyngeal, and 
laryngeal cancers did not vary according to years of drinking, suggesting no effect of duration. For 
oropharyngeal cancer, the risk increased with durations up to 28 years, flattening thereafter. The risk peaked 
at the higher levels of intensity and duration for all sub-sites (odds ratio=7.95 for oral cavity, 12.86 for 
oropharynx, 24.96 for hypopharynx, and 6.60 for larynx). 
Conclusions: Present results further encourage the reduction of alcohol intensity to mitigate HNC risk. 
 
Keywords: bivariate spline models; alcohol drinking duration; alcohol drinking intensity; head and neck 





Worldwide, harmful alcohol consumption causes 3 million deaths each year (5% of all deaths), and it is 
responsible for approximately 5% of the global burden of disease and injury.1 In particular, alcohol 
consumption has been consistently associated with cancer risk at several sites.2 Together with tobacco 
smoking, alcohol drinking is one the major risk factors for head and neck cancer (HNC), and it is responsible 
for approximately one third of the cases worldwide.3-4 
Epidemiological studies firmly established a clear dose-response relationship between ethanol intake and 
HNC risk.5-6 However, alcohol drinking has two related dimensions impacting on health outcomes: besides the 
quantity of alcohol consumed, time-related patterns of consumption, such as age at starting and duration, have 
a relevant role1 and they may modify the reported association between drinking intensity and cancer risk. 
Notably, a joint effect of intensity and duration on cancer risk has already been reported for tobacco smoking 
in HNC7-8 and in other tobacco-related cancers.9-11 
In a previous analysis from the International Head and Neck Cancer Epidemiology (INHANCE) consortium 
including 15 studies,7 the independent contribution of drinking intensity and duration was estimated through 
the calculation of drink-years. Similarly to pack-years for tobacco smoking, drink-years represent the lifetime 
cumulative exposure to alcohol, and it was obtained by multiplying intensity (in drinks/day) by duration (in 
years). Then, the effect of duration on HNC risk was estimated analysing the risk for drink-years within fixed 
categories of intensity; this analysis reported an independent effect of drinking duration for all HNC sub-sites.7  
In the absence of a clear relationship between alcohol intensity and duration on the risk of HNC, we 
investigated their joint effect on the INHANCE database using an extension of the bivariate spline model 
presented in a previously published analysis on cigarette smoking.8 Differently from the previous INHANCE 
paper,7 this model allows risks to vary for different combinations of drinking intensity and duration, even when 
the cumulative drink-year exposure is the same. We will address the following research questions: 1. What are 
the relationships between intensity and duration of alcohol drinking and the risk of cancer at HNC sub-sites? 
2. Do drinking intensity and duration have a similar impact on HNC risk? 3. Are there meaningful values of 




Materials and Methods 
The INHANCE consortium was established in 2004 to elucidate the aetiology of HNC through pooled 
analyses of individual-level data from several studies on a large scale.12-13 It included invasive cancer cases of 
the oral cavity, oropharynx, hypopharynx, oral cavity or pharynx not otherwise specified, larynx, or 
unspecified HNC. Cases with cancers of the salivary glands or of the nasal cavity/ear/paranasal sinuses were 
excluded.14 
At the time of this analysis, the INHANCE database (version 1.5) included 25 716 HNC cases and 37 111 
controls (http://www.inhance.utah.edu, last access 25th May, 2020). The present analysis was restricted to 26 
case-control studies (21 384 HNC cases; 30 651 controls) that collected information on alcohol drinking status 
(i.e., never, former, current), intensity (number of drinks/day), and duration (years) at individual level 
(Supplementary Table S1).15-40 Cancer sites were grouped according to similar major aetiology:  oral cavity 
(ICD10 codes: C02-C06; n=6 249), oropharynx (ICD10: C01, C09-C10; n=5 499), hypopharynx (ICD10: C13; 
n=1 798), and larynx (ICD10: C32; n=5 620). The following exclusion criteria were applied: a) cancers arising 
in sites other than those mentioned above, or mixed cancer sub-sites (2 218 subjects); b) missing information 
on drinking status, intensity, or duration (2 247 subjects); c) being former drinkers (i.e., having stopped 
drinking for at least one year before cancer diagnosis or interview for controls; 6 993 subjects), as these subjects 
are more likely to stop drinking for reasons related to medical conditions;41 d) missing information on major 
covariates, namely sex, age, education, ethnicity (92 subjects), or on cigarette smoking status, intensity, or 
duration (392 subjects) (see the flow-chart in Supplementary Figure S1). In 15 studies15-
17,19,21,22,24,25,27,28,33,34,37,38,40 controls were selected among cancer-free patients admitted to hospital for non-
oncologic reasons, whereas controls were from the general population in 9 studies;18,20,23,29-32,36,39 two 
multicentre studies26,35 enrolled a combination of hospital and population controls.  
To prevent potential estimation distortion due to sparse data or misclassification at the highest levels of the 
exposure distributions, we further excluded subjects who reported the highest 5% of drinking intensity (i.e., 
>10 drinks/day) or duration (i.e., >54 years); consequently, 2 455 HNC cases (17.3%) and 1 637 controls 
(6.3%) were excluded. Finally, the current analysis included 4 085 individuals with cancers of the oral cavity, 
3 359 oropharynx, 983 hypopharynx, 3 340 larynx, and 24 234 controls (Supplementary Table S2). For those 
studies reporting a case-control matching, separate sets of controls were matched for the three cancer sub-sites. 
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Informed consent was obtained from all study subjects (Supplementary Table S1). The investigations were 
approved by the relevant Boards of Ethics, according to the regulation in force at time the data were collected. 
Available data were harmonized at the Study Coordinating Center.14 While different studies had used 
different definitions of alcohol drinking status, the current paper defined as never drinkers those individuals 
who have never had any alcohol (0 ml of ethanol or 0 drinks over lifetime), or were defined as never drinkers 
by the individual studie. A similar definition was adopted for smoking habits.8 Study subjects were asked to 
report their drinking habits (drinking status, intensity and duration). Drinking intensity was then expressed in 
drinks/day of alcoholic beverages. To account for variation of ethanol content across alcoholic beverages and 
across countries, intensity was harmonized on a standard drink, corresponding to 15.6 ml (i.e., 12 g) of ethanol, 
weighting intensity by study-specific beverages volume and ethanol intake.14 Average lifetime alcohol intake 
was calculated as the total intake of wine, beer, and hard liquor, taking into account possible intensity 
modification or quitting periods occurring in subjects’ life. Duration of alcohol drinking was calculated as the 
period of time between the subject’s age at the start of drinking any alcoholic beverages and the age at cancer 
diagnosis (or interview, for controls), discarding periods when the subject abstained from any alcoholic 
beverages.  
The dose-response relationship between cancer risk and the joint exposure to alcohol drinking intensity and 
duration in current drinkers was investigated through bivariate regression spline models,42 as described 
elsewhere.8,43 In contrast to drink-years, this method allows risks to vary for different combinations of the two 
continuous exposures intensity and duration, even when the cumulative drink-year exposure is the same (i.e., 
people drinking 1 drink/day for 10 years are allowed to have a different risk than those drinking 10 drinks/day 
for one year). Briefly, within a generalized semi-parametric logistic regression model, the two exposures were 
entered as a joined piecewise polynomial of a linear degree with constraints for continuity at each join point 
(called knot), together with potential confounders. Knots represented change points, where the slope of the 
risk surface changes to account for potential departures from linearity. The set of spline regression parameters 
described the shape of the risk surface. For each cancer sub-site, the optimal number of knots, their location, 
the regression and spline coefficients were jointly estimated within the Bayesian approach43. Vague prior 
distributions were assumed on the regression and spline coefficients, with spike-and-slab priors on the spline 
coefficients managing the choice of the optimal number of knots within a modified Stochastic Search Variable 
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Selection approach.44 The Markov Chain Monte Carlo (MCMC)-type NUTS (No-U-Turn Sampler) 
algorithm8,45-46 allowed to implement the Stochastic Search Variable Selection approach for identifying the 
optimal number of knots and then to derive the final joint posterior distribution of all the parameters, with the 
optimal combination of number of knots previously identified. Convergence was tested by algorithm-specific 
and generic MCMC diagnostics, reporting low number of divergences, a R-hat statistic<1.05 for each 
parameter, and a generally high effective sample size, suggesting the chains efficiently explored the posterior 
distribution. For each sub-site, the ORs and their 95% credible intervals (CIs) were derived from the 
corresponding (final) posterior distribution. The ORs were presented through three-dimensional plots that 
displayed the surface of risk for any combination of alcohol drinking intensity and duration. In addition, we 
presented two-dimensional plots that displayed patterns of risks corresponding to one variable exposure for 
fixed levels of the other exposure. All the models were fitted with the full set of potential confounders, i.e., 
sex, age, study, race, education, cigarette smoking status, cigarette smoking intensity, cigarette smoking 
duration, and pipe and cigar status (Supplementary Table S2); ‘‘Never drinkers’’ were assumed as the reference 




 Study subjects were predominantly males (70.7%); the median age was 58 years for controls and for all 
cases together. Current smoking was reported in the majority of cancer patients (51.5% of oral cavity, 52.4% 
of oropharyngeal cancers, 63% of hypopharyngeal, and 61.2% of laryngeal cancers), but not in the controls 
(24.2%; Supplementary Table S2).  
In the study population (Table 1), patients with cancer of the oral cavity who were current drinkers drank 
at higher intensities (but not for a longer time period) than controls. The proportion of never drinkers was much 
lower among patients with oropharyngeal (17.4%), hypopharyngeal (8.9%), and laryngeal (17.8%) cancers; 
drinking habits in these cancers showed a higher intensity and a longer duration. 
The surfaces of HNC cancer risk for the joint exposure to drinking intensity and duration were displayed 
in Figure 1. For all sub-sites, the risk steeply increased with increasing number of drinks/day, with no 
appreciable threshold effect at lower intensities. The risk peaked at the higher levels of duration and intensity 
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(i.e., for people drinking 10 drinks/day for 54 years) for all sub-sites, reaching ORs of 8.0 (95% CI: 4.6-13) 
for oral cavity, 12.9 (95% CI: 7.2-23.7) for oropharynx, 25.0 (95% CI: 11.6-51.5) for hypopharynx, and 6.6 
(95% CI: 4.9-9) for larynx. For oral cavity (Figure 1.a) and hypopharynx (Figure 1.c), the risk flattened after 
5 and 4 drinks/day, respectively. Moreover, the risk surfaces for cancers of the oral cavity, hypopharynx, and 
larynx (Figure 1.a, 1.c, and 1.d) suggested no effect of drinking duration in addition to intensity: the risk 
remained stable when duration increased, for fixed levels of intensity. For oropharyngeal cancer (Figure 1.b), 
the risk increased with increasing years of duration up to 28 years, flattening thereafter; this effect was more 
marked at higher intensities. A sensitivity analysis conducted excluding only extremely high values (i.e., 
intensity >28 drink/day or >61 years, 1% of study subjects) showed similar results. The same analyses were 
further conducted in strata of gender (Supplementary Figure S2): risk surfaces were similar in shape to those 
in the main analysis, even if cancer risk was slightly higher for women than for men. The subgroup analysis 
was not performed for the hypopharynx sub-site, due to low number of cases. 
The same effects between alcohol intensity and duration across HNC sub-sites are also shown in Figure 2, 
which presents the risk for increasing intensities at defined duration levels (upper panels), and the risk for 
increasing durations at defined levels of intensity (lower panels). For cancers of the oral cavity, hypopharynx, 
(Figure 2.a) and larynx (Figures 2.a, 2.c, and 2.d), the curves for intensity at different durations were largely 
overlapping and showed an upward trend. This indicated that duration did not substantially modify cancer risk, 
which was mainly driven by drinking intensity. Figures 2.e, 2.g, and 2.h confirmed this conclusion, showing 
generally flat curves for the three levels of intensities up to 5 drinks/day, as also suggested by the CIs 
(Supplementary Table S3); a modest upward trend was present at the highest intensity level (i.e., 10 
drinks/day). Differently, a joint effect of intensity and duration was found for oropharyngeal cancer risk: the 
risk increased with increasing intensities, but higher levels of duration raised up the curves to the highest risk 
(Figure 2.b); duration increased oropharyngeal cancer risk up to approximately 28 years (Figure 2.f), although 







The present analyses show that, consistently between genders, drinking intensity was the predominant 
measure of alcohol affecting the risk of oral cavity, hypopharyngeal, and laryngeal cancers, whereas the 
contribution of duration, for fixed alcohol intensities, was modest. Notably, this suggests that drinking alcohol 
beverages, even for a short period, increases the risk at these cancer sub-sites and that duration of alcohol use 
has little or no consistent effect on the risk of these cancers. Differently, there was a joint effect of drinking 
intensity and duration in determining oropharyngeal cancer risk.  
The direct association between alcohol intensity and HNC risk has been extensively described2,6,49 and 
potential mechanisms have been proposed.5,50 Ethanol is oxidized to alcohol acetaldehyde (AA), which is a 
recognized carcinogen.2 Alcohol may also have a local effect, acting as a solvent of cell membranes to enhance 
the penetration of carcinogens, notably those from tobacco smoking, into the mucosa.50 Further, nutritional 
deficiencies may occur in alcoholics.50 
The relationship between drinking duration and HNC risk was more complex, with a clear association with 
oropharyngeal cancer risk up to approximately 28 years of drinking. These results are in agreement with 
previous findings derived from a standard approach on a smaller set of INHANCE studies (15 studies) 
including never smokers only, which showed no association with alcohol duration in all HNC sub-sites but 
hypo-/oropharynx.14 Furthermore, the application of a different statistical approach7 on the 15 INHANCE 
studies supported the presence of a stronger association with intensity than with duration for HNC risk. 
Although the lack of association with duration may seem counterintuitive, it has been reported in oesophageal 
adenocarcinomas, another alcohol-related cancer, in a large pooled analysis on 12 case-control studies.51 
Although these results did not allow to draw biological interpretations, they suggest that alcohol intake acts as 
a late-stage carcinogen.52  
A major limitation of the present study was information bias, which may have occurred as a consequence 
of the complexity of lifetime drinking patterns. Changes in the intensity, in type of alcohol beverages, and 
temporary quitting are more frequent for alcohol drinking than for other lifestyle habits,53 such as tobacco 
smoking; lifetime patterns may have an impact on the risk of cancer.54 Therefore, misclassification may have 
occurred for both intensity and duration. The calculation of lifetime average alcohol intake may have protected 
against this source of bias, thus not allowing the investigation of specific drinking patterns (e.g., infrequent 
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heavy binge drinking). In addition, the use of linear bi-dimensional spline models may have contributed too, 
as they are quite robust with respect to small variations in the predictors, as compared to bi-dimensional splines 
of higher degrees. To test for model robustness, we adopted different solutions of truncation or approximation 
of drinking intensity and duration, and the resulting surface estimates were similar. Further, self-reporting of 
drinking habits may have led to additional information bias, since higher values of intensity and duration are 
more prone to inaccurate reporting.55-56 To reduce information bias and residual confounding at the extreme 
values of the exposure distributions, we excluded subjects reporting higher (>95th percentiles) drinking 
intensity and/or duration from the present analysis; however, this could have led to a reduced study power and 
differential exclusion of cases and controls. Finally, our Bayesian approach was computationally time 
consuming, requiring dedicated server devices. 
Although risk estimates were adjusted for tobacco smoking (considering cigarettes, cigars, and pipes), 
some residual confounding may remain. An analysis among never smokers would rule out possible residual 
confounding due to tobacco smoking. However, considering that the present logistic models includes several 
covariates, they require large sample sizes to produce precise estimates; thus,  we were unable to conduct this 
subgroup analysis with sufficient precision. Nonetheless, the previously cited INHANCE analysis on never 
smokers14 reported results similar to the current ones, with HNC risk generally increasing with alcohol intensity 
and no dose-response relation with drinking duration. Further, the lack of information on infection with human 
papilloma virus (HPV) has to be accounted among study limitations, considering the recognized role of  HPV 
in oropharyngeal cancer.57 Unfortunately, HPV status was not collected in the majority of studies, since they 
were conducted before the awareness of the HPV role in oropharyngeal cancer. International 
representativeness is guaranteed by the large dataset including studies from different geographical areas. On 
the other hand, the inclusion of heterogeneous populations, in particular that of genetic origin, may have led 
to estimation bias. Compared to other populations, East Asians have a much higher frequency of A allele of 
ALDH2 rs671,58 which slows acetaldehyde metabolism, thus increasing alcohol-related risk. However, the 
exclusion of East Asian studies16,33 did not substantially modify the risk estimates.  
Results of the present study are strengthened the availability of information on several potential 
confounding factors. In addition, we applied a Bayesian approach to jointly estimate the optimal knot locations 
and the ORs of HNC for the joint effect of our continuous predictors.8 As compared to the companion paper 
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on cigarette-smoking intensity and duration, in the current application the optimal number of knots was 
estimated within a two-step procedure including the Stochastic Search Variable Selection approach43. To our 
knowledge, this is the first time that a similar approach is applied within the context of spline models in 
epidemiology.  
In conclusion, findings of the present study indicate that the risk of cancer of the oral cavity, hypopharynx, 
and larynx increases with drinking intensity, whereas the role of duration is complex. The trend is linear for 
larynx, but it showed a plateaux at the highest intensity for cancer of the oral cavity and hypopharynx. The 
joint effect of  intensity and duration increases the risk of oropharyngeal cancer. In addition, no threshold effect 
is evident at the lowest doses. Although abstinence from alcohol drinking would be the ultimate goal to reduce 
HNC incidence, these findings suggest that any reduction in alcohol intake59 would be an effective strategy to 
mitigate HNC risk, as well as the risk of few other neoplasms.60 
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Figure 1. Bivariate spline models estimates of odds ratios of oral cavity (a), oropharyngeal (b), 
hypopharyngeal (c), and laryngeal (d) cancers in current drinkers for the joint effect of intensity and duration 
of alcohol consumption. On the grid, black thicker lines represent knot locations, at 5 drinks/day for oral cavity, 
at 4 drinks/day for hypopharyngeal cancer, and at 28 years for oropharyngeal cancer. INHANCE consortium. 
 
Figure 2. Bivariate spline models estimates of odds ratios of oral cavity, oropharyngeal, hypopharyngeal, and 
laryngeal cancers in current drinkers for alcohol intensity and fixed levels of alcohol duration (a. to d.) and for 






Table 1 - Distribution of cases of oral cavity, oropharyngeal, hypopharyngeal, and laryngeal cancers, and 
controls according to intensity and duration of alcohol drinking in current drinkers. INHANCE consortium 
 Controls Oral cavity Oropharynx Hypopharynx Larynx 
 n (%) n (%) n (%) N (%) n (%) 
           
Total 24 234  4 085  3 359  983  3 340  
           
Never 
drinkers 
7 873 (32.5) 1,353 (33.1) 583 (17.4) 87 (8.9) 593 (17.8) 
           
Drinking intensity (drinks/day) 
≤1 6 921 (28.6) 757 (18.5) 801 (23.8) 105 (10.7) 583 (17.5) 
>1-≤3 5 470 (22.6) 805 (19.7) 787 (23.4) 242 (24.6) 771 (23.1) 
>3-≤10 3 970 (16.4) 1 170 (28.6) 1 188 (35.4) 549 (55.8) 1 393 (41.7) 
           
Drinking duration (years) 
1-30 6 218 (25.7) 975 (23.9) 889 (26.5) 217 (22.1) 647 (19.4) 
31-40 5 061 (20.9) 920 (22.5) 1 049 (31.2) 337 (34.3) 986 (29.5) 
41-54 5 082 (21.0) 837 (20.5) 838 (24.9) 342 (34.8) 1 114 (33.4) 
           
Age at start drinking (years) 
≤18 5 482 (22.6) 1,047 (25.6) 1 172 (34.9) 324 (33.0) 1 050 (31.4) 
19-25 7 016 (29.0) 1,110 (27.2) 1 126 (33.5) 423 (43.0) 1 209 (36.2) 
26-35 2 435 (10.0) 332 (8.1) 328 (9.8) 106 (10.8) 331 (9.9) 
>35 1 428 (5.9) 243 (5.9) 150 (4.5) 43 (4.4) 157 (4.7) 








(a) Oral cavity (b) Oropharynx
(d) Larynx(c) Hypopharynx








Supplementary Table S1. Characteristics of the individual studies from the International Head and Neck Cancer Epidemiology (INHANCE) consortium used in 
the current analysis. INHANCE consortium. 















Milan (1984-1989), Italy Hospital <80 95¹ Hospital - unhealthy 95¹ -- 1984-1989 
Aviano, Italy Hospital >18 >951 Hospital - unhealthy 95¹ -- 1987-1992 
France (1987-1992), France  Hospital NA 95¹ Hospital - unhealthy 95¹ Age, sex, hospital 1987-1992 
Italy Multicenter Hospital 18-80 >95 Hospital - unhealthy >95 -- 1990-1999 
Switzerland Hospital <80 >95 Hospital - unhealthy >95 -- 1991-1997 
New York, NY, USA (multicenter) Hospital 21-80 91 Hospital- unhealthy 97 
Age, sex, hospital, 
year of interview 
1981-1990 
Seattle (1985-1995), WA, USA 
Cancer 
registry 
18-65 54.4,63.3² Random digit dialing 63.0,60.9² Age, sex 1985-1995 
Iowa, IA, USA Hospital >18 87 Hospital - unhealthy 92 Age, sex 1993-2006 
North Carolina (1994-1997), NC, 
USA 
Hospital >17 88 Hospital - unhealthy 86 Age, sex 1996-1997 
Tampa, FL, USA Hospital ≥18 98 Hospital - noncancer 90 Age, sex, ethnicity 1994-2003 
Los Angeles, CA, USA 
Cancer 
registry 











83 Age, sex 1992-1995 
Latin America Hospital 15-79 95 Hospital - unhealthy 86 
Age, sex, ethnicity, 
city 
2000-2003 
International Multicenter, IARC Hospital NA 88,7 Hospital/Community 87,3 Age, sex, center 1992-1997 




Sao Paulo, Brazil Hospital NA  Hospital-unhealthy  
age, sex, city of 
residence, hospital 
2002-2007 
New York (MSKCC), NY, USA Hospital NA -- Blood donors -- Age, sex 1992-1994 
Seattle-Leo, WA, USA 
Cancer 
registry 
20-74 81 Random digit dialing 75 Age, sex 1983-1987 














20-79 97,00 Hospital - unhealthy 97,00 Age, sex 2001-2005 




20-80 82 DMV files 61 Age, sex, ethnicity 2002-2006 
France Multicenter (2001-2007) 
Cancer 
registry 
<=75 82,5 Random digit dialing 80,6 Age, sex, region 2001-2007 
Baltimore, MD, USA 
Hospital NA 100 
Hospital - benign 
conditions 
70 
age, sex, HPV 
status 
2000-2005 
Beijing, China Hospital 18-80 100 Hospital 100 Age, sex 1988-1989 
Milan (2006-2009), Italy Hospital 18-80 >95 Hospital >95 ---- 2006-2009 
ABBREVIATIONS: ARCAGE: Alcohol-Related Cancers And Genetic susceptibility in Europe; DMV: Department of Motor Vehicles; HPV: Human Papilloma Virus; IARC: 
International Agency for Research on Cancer; MSKCC: Memorial Sloan Kettering Cancer Center; NA: Not Available. 
 
a Participation rate was not formally assessed, estimated response rate reported. 
b Two response rates are reported because data were collected in two population-based case-control studies, the first from 1985 to 1989 among men and the second 






Supplementary Table S2. Distribution of cases of oral cavity, oropharyngeal, hypopharyngeal, and laryngeal 
cancers, and controls according to selected variables. INHANCE consortium 
 Controls Oral cavity Oropharynx Hypopharynx Larynx 
 n (%) n (%) n (%) n (%) n (%) 
TOTAL 24,234 (100) 4,085 (100) 3,359 (100) 983 (100) 3,340 (100) 
           
Sexa           
Female 7,533 (31.1) 1,552 (38.0) 780 (23.2) 138 (14.0) 533 (16.0) 
Male 16,701 (68.9) 2,533 (62.0) 2,579 (76.8) 845 (86.0) 2,807 (84.0) 
           
Age (years)a           
<40 1,720 (7.1) 284 (7.0) 124 (3.7) 7 (0.7) 68 (2.0) 
40 to 44 1,711 (7.1) 234 (5.7) 211 (6.3) 38 (3.9) 116 (3.5) 
45 to 49 2,479 (10.2) 442 (10.8) 449 (13.4) 104 (10.6) 294 (8.8) 
50 to 54 3,547 (14.6) 645 (15.8) 617 (18.4) 184 (18.7) 493 (14.8) 
55 to 59 4,217 (17.4) 743 (18.2) 727 (21.6) 211 (21.5) 682 (20.4) 
60 to 64 3,944 (16.3) 670 (16.4) 542 (16.1) 182 (18.5) 671 (20.1) 
65 to 69 3,431 (14.2) 492 (12.0) 409 (12.2) 144 (14.6) 603 (18.1) 
70 to 74 2,304 (9.5) 336 (8.2) 206 (6.1) 92 (9.4) 310 (9.3) 
≥75 881 (3.6) 239 (5.9) 74 (2.2) 21 (2.1) 103 (3.1) 
           
Study name           
Aviano 652 (2.7) 52 (1.3) 71 (2.1) 38 (3.9) 91 (2.7) 
Baltimore 162 (0.7) 36 (0.9) 83 (2.5) 4 (0.4) 31 (0.9) 
Beijing 380 (1.6) 377 (9.2)       
Boston 400 (1.7) 90 (2.2) 145 (4.3) 22 (2.2) 68 (2.0) 
France (1987-1992) 194 (0.8) 41 (1.0) 50 (1.5) 27 (2.7) 127 (3.8) 
France Multicenter (2001-2007) 3,149 (13.0) 343 (8.4) 489 (14.6) 275 (28.0) 368 (11.0) 
Houston 712 (2.9) 182 (4.5) 306 (9.1) 30 (3.1) 108 (3.2) 
International Multicenter 1,297 (5.4) 640 (15.7) 224 (6.7)   2 (0.1) 
Iowa 550 (2.3) 173 (4.2) 97 (2.9) 7 (0.7) 60 (1.8) 
Italy Multicenter 2,246 (9.3) 126 (3.1) 193 (5.7) 77 (7.8) 324 (9.7) 
Japan (2001-2005) 2,796 (11.5) 100 (2.4) 63 (1.9) 63 (6.4) 80 (2.4) 
Latin America 993 (4.1) 199 (4.9) 154 (4.6) 66 (6.7) 367 (11.0) 
Los Angeles 815 (3.4) 34 (0.8) 93 (2.8) 8 (0.8) 51 (1.5) 
Milan (1984-1989) 1,450 (6.0) 40 (1.0) 32 (1.0) 25 (2.5) 229 (6.9) 
Milan (2006-2009) 568 (2.3) 64 (1.6) 10 (0.3) 9 (0.9) 145 (4.3) 
MSKCC 89 (0.4) 34 (0.8) 5 (0.1) 5 (0.5) 24 (0.7) 
New York Multicenter 1,098 (4.5) 303 (7.4) 286 (8.5) 17 (1.7) 123 (3.7) 
North Carolina (1994-1997) 157 (0.6) 28 (0.7) 24 (0.7) 10 (1.0) 25 (0.7) 
North Carolina (2002-2006) 962 (4.0) 99 (2.4) 218 (6.5) 33 (3.4) 239 (7.2) 
Puerto Rico 278 (1.1) 25 (0.6) 35 (1.0) 10 (1.0)   
Sao Paulo 1,145 (4.7) 347 (8.5) 111 (3.3) 52 (3.4) 224 (6.7) 
Seattle (1985-1995) 502 (2.1) 160 (3.9) 113 (3.4)     
Seattle-Leo 431 (1.8) 113 (2.8) 85 (2.5) 29 (3.0) 116 (3.5) 
Switzerland 823 (3.4) 109 (2.7) 110 (3.3) 72 (7.3) 111 (3.3) 
Tampa 738 (3.0) 16 (0.4) 37 (1.1) 1 (0.1) 38 (1.1) 





Supplementary Table S2. Continued 
Racea           
Asian and Pacific Islanders 3,779 (15.6) 833 (20.4) 132 (3.9) 64 (6.5) 87 (2.6) 
Black 631 (2.6) 149 (3.6) 108 (3.2) 30 (3.1) 109 (3.3) 
Hispanic 304 (1.3) 29 (0.7) 37 (1.1) 2 (0.2) 7 (1.0) 
Others and Brazilians 2,267 (9.3) 564 (13.8) 301 (9.0) 121 (12.3) 598 (17.9) 
White 17,253 (71.2) 2,510 (61.4) 2,781 (82.8) 766 (77.9) 2,514 (75.3) 
           
Educationa           
No education 980 (4.0) 472 (11.6) 55 (1.6) 32 (3.3) 94 (2.8) 
≤Junior high school 8,408 (34.7) 1,341 (32.8) 969 (28.8) 409 (41.6) 1,495 (44.8) 
Some high school 4,340 (17.9) 787 (19.3) 715 (21.3) 257 (26.1) 632 (18.9) 
High school graduate 3,097 (12.8) 567 (13.9) 510 (15.2) 121 (12.3) 458 (13.7) 
Technical sch., some college 3,680 (15.2) 513 (12.6) 559 (16.6) 90 (9.2) 408 (12.2) 
≥College graduate 3,729 (15.4) 405 (9.9) 551 (16.4) 74 (7.5) 253 (7.6) 
           
Cigarette smoking status            
Never user 10,570 (43.6) 1,263 (30.9) 660 (19.6) 72 (7.3) 223 (6.7) 
Former user 7,804 (32.2) 717 (17.6) 939 (28.0) 292 (29.7) 1,072 (32.1) 
Current user 5,860 (24.2) 2,105 (51.5) 1,760 (52.4) 619 (63.0) 2,045 (61.2) 
           
Cigarette smoking intensity (cigarettes/day)   
≥1-10 4,046 (16.7) 475 (11.6) 452 (13.5) 138 (14.0) 352 (10.5) 
>10-20 5,837 (24.1) 1,254 (30.7) 1,157 (34.4) 391 (39.8) 1,366 (40.9) 
>20-30 1,826 (7.5) 567 (13.9) 503 (15.0) 186 (18.9) 657 (19.7) 
>30-40 1,301 (5.4) 373 (9.1) 412 (12.3) 149 (15.2) 503 (15.1) 
>40 654 (2.7) 153 (3.7) 175 (5.2) 47 (4.8) 239 (7.2) 
           
Cigarette smoking duration (years)   
1-10 1,801 (7.4) 132 (3.2) 166 (4.9) 20 (2.0) 72 (2.2) 
11-20 2,696 (11.1) 228 (5.6) 220 (6.5) 56 (5.7) 169 (5.1) 
21-30 3,426 (14.1) 572 (14.0) 562 (16.7) 172 (17.5) 523 (15.7) 
31-40 3,327 (13.7) 1,004 (24.6) 968 (28.8) 347 (35.3) 1,084 (32.5) 
>40 2,414 (10.0) 886 (21.7) 783 (23.3) 316 (32.1) 1,269 (38.0) 
           
Cigar smoking status           
Never user 19,438 (80.2) 3,347 (81.9) 2,991 (89.0) 853 (86.8) 3,023 (90.5) 
Current user 1,004 (4.1) 186 (4.6) 248 (7.4) 57 (5.8) 197 (5.9) 
Unknown 3,792 (15.6) 552 (13.5) 120 (3.6) 73 (7.4) 120 (3.6) 
           
Pipe smoking status           
Never user 20,269 (83.6) 3,719 (91.0) 3,073 (91.5) 862 (87.7) 3,074 (92.0) 
Current user 1,125 (4.6) 242 (5.9) 205 (6.1) 52 (5.3) 164 (4.9) 
Unknown 2,840 (11.7) 124 (3.0) 81 (2.4) 69 (7.0) 102 (3.1) 
 
ABBREVIATIONS: MSKCC: Memorial Sloan Kettering Cancer Center. 
a We excluded subjects with missing information on age, sex, race and cigarette smoking habits.  Missing 






Supplementary Table S3. Odds Ratio (OR) and 95% Credible Intervals (CI) of cases of oral cavity, 
oropharyngeal, hypopharyngeal, and laryngeal cancers, for selected levels of alcohol intensity and duration. 
INHANCE consortium 
  Oral cavity Oropharynx Hypopharynx Larynx 
  OR  95% CI OR  95% CI OR  95% CI OR  95% CI 





        
1 5 1.40 1.30-1.51 1.25 1.14-1.36 1.84 1.58-2.20 1.14 1.08-1.20 
 10 1.38 1.29-1.48 1.38 1.26-1.52 1.81 1.55-2.17 1.12 1.06-1.19 
 20 1.35 1.25-1.45 1.67 1.46-1.99 1.76 1.48-2.13 1.09 1.01-1.17 
 40 1.28 1.14-1.44 1.56 1.16-2.73 1.67 1.28-2.21 1.03 0.90-1.16 
          
2 5 1.97 1.72-2.29 1.44 1.19-1.70 3.35 2.52-4.83 1.32 1.20-1.46 
 10 1.94 1.71-2.21 1.61 1.39-1.86 3.25 2.49-4.55 1.31 1.20-1.44 
 20 1.86 1.68-2.08 2.01 1.74-2.40 3.07 2.42-4.14 1.29 1.18-1.41 
 40 1.73 1.54-1.94 1.97 1.45-2.73 2.73 2.10-3.64 1.25 1.10-1.40 
          
5 5 5.52 3.92-7.97 2.19 1.35-3.32 11.95 6.94-25.47 2.07 1.63-2.65 
 10 5.32 3.96-7.32 2.56 1.81-3.53 11.41 6.93-23.31 2.09 1.70-2.60 
 20 4.95 3.95-6.27 3.49 2.88-4.38 10.38 6.85-19.58 2.14 1.83-2.52 
 40 4.29 3.59-5.16 3.93 2.92-6.03 8.58 6.06-15.20 2.23 1.96-2.52 
          
10 5 6.07 1.99-13.49 4.43 1.64-10.13 21.62 4.45-82.86 4.37 2.71-7.15 
 10 6.23 2.32-12.67 5.55 2.74-10.53 21.65 5.31-75.35 4.56 3.01-6.98 
 20 6.54 3.19-11.13 8.79 6.16-12.65 21.91 7.43-65.55 4.95 3.66-6.77 
 40 7.32 4.75-10.31 12.48 8.89-22.72 23.29 11.85-51.70 5.88 4.83-7.16 





Legends to supplementary figures 
Supplementary Figure S1. Flow-chart of subjects’ selection process. INHANCE consortium. 
 
Supplementary Figure S2. Bivariate spline models estimates of odds ratios of oral cavity, oropharyngeal, and 
laryngeal cancers in current drinkers for the joint effect of intensity and duration of alcohol consumption, in 
strata of gender. On the grid, black thicker lines represent knot locations, at 5 drinks/day for oral cavity in men, 









Supplementary Figure S2. 
 
